XLON
RKT
Market cap38bUSD
, Last price
GBX
Name
Reckitt Benckiser Group PLC
Chart & Performance
P/E
—
P/S
—
EPS
2.25
Div Yield, %
—
Shrs. gr., 5y
-0.20%
Rev. gr., 5y
1.98%
Revenues
14.17b
-3.00%
Net income
1.43b
-13.21%
CFO
2.68b
+1.75%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Reckitt Benckiser Group plc develops, manufactures, and distributes a diverse range of health, hygiene, and nutrition products across global markets, including the United Kingdom, the United States, China, and India. Its extensive health portfolio features Clearasil for acne treatment; Dettol for disinfection, hygiene, and first aid; and Durex and K-Y, offering condoms, sex toys, and lubricants. Digestive relief solutions include Gaviscon for heartburn and indigestion. For pain and cold management, it provides Nurofen and Biofreeze analgesics, Strepsils and Cepacol for sore throats, and Mucinex and Delsym for cough, chest congestion, and sinus remedies. Hair removal needs are met by the Veet brand. In hygiene and home care, the company offers Air Wick fragrances and devices, Calgon water softeners, and a variety of cleaning solutions such as Cillit Bang, Finish for dishwashing, Harpic toilet cleaners, Lysol disinfectants, and Easy-Off for general cleaning. Pest control is addressed with Mortein sprays, baits, and plug-ins, while Vanish and Woolite handle stain removal and fabric washing. RID-X provides septic tank system treatments, and Botanical Origin offers plant-based laundry products. The nutrition segment includes prominent infant and toddler nutrition brands like Enfamil, Mead Johnson, and Nutramigen, specializing in baby formulas and other related products. Adult nutrition and supplements are available through Airborne (vitamins/minerals), Move Free (joint support), MegaRed (Omega products), Neuriva (brain health), and Bodi-Ome and Digestive Advantage (probiotics). Established in 1819, Reckitt Benckiser Group plc maintains its headquarters in Slough, United Kingdom.
Valuation
Title GBP in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||